Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Encapsulated Compounds/ TB-500 Capsules
In stock
TB-500 Capsules

TB-500 Capsules

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

When a cell needs to move, rebuild a wound edge, or sprout a new vessel, it first has to remodel its own internal scaffolding — and that scaffolding is actin. TB-500 is the synthetic counterpart of the active region of Thymosin β-4, a 43-amino-acid actin-sequestering peptide that sits at the heart of how cells reshape themselves during migration and repair. It has become a reference tool for laboratories probing the molecular choreography of tissue regeneration.

An actin-binding peptide drawn from a developmental regulator. Thymosin β-4 is one of the most abundant actin-binding proteins in many cell types, and its expression has been mapped across human organ development, marking it as a deeply conserved player in tissue formation (Faa et al., 2024). TB-500 reproduces the G-actin-binding motif responsible for much of that activity, which is why it is studied as a probe for cell motility, angiogenesis and regenerative signalling.

Beyond simple actin handling, the parent molecule has been framed as a candidate for anti-ageing and regenerative paradigms, with research mapping new mechanistic directions for the peptide family (Bock-Marquette et al., 2023).

What the research explores. Across cell-culture and animal systems, TB-500 has been investigated along several converging lines:

  • Cardiac repair & remodelling — examined in ischaemic and post-infarction models, where recombinant thymosin β-4 has been studied for effects on cardiac dysfunction and ROCK1-linked remodelling (Zhang et al., 2025; Maar et al., 2025).
  • Corneal & wound-healing models — explored as a driver of epithelial repair, including engineered tandem-thymosin constructs in corneal wound-healing systems (Nguyen et al., 2025).
  • Tissue protection & regenerative biology — studied in kidney-disease paradigms and graft-survival models tied to the Rac/F-actin and mitochondrial-transfer pathways (Di et al., 2026; Zhang et al., 2025).

The activity described here is drawn from in-vitro and animal studies; it characterises biological behaviour in experimental models and does not establish efficacy or safety in humans. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS No. 77591-33-4 · Molecular formula C212H350N56O78S · Molecular weight 4963.44 g/mol · Sequence Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (43 aa) · Appearance: White lyophilized powder · Solubility: Soluble in water.

Specification & quality. Each bottle contains 60 HPMC (vegan) capsules, each providing 500mcg of TB-500 at ≥99% (HPLC). Encapsulated — no reconstitution required. Every batch is independently third-party tested, and a Certificate of Analysis (COA) is available. Store at -20°C, protect from light and moisture; shelf life 24 months from the manufacture date. EU warehoused.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number77591-33-4
Molecular formulaC212H350N56O78S
Molecular weight4963.44
SequenceAc-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (43 aa)
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity60 capsules
SolubilitySoluble in water
StorageStore at -20°C, protect from light and moisture
ReconstitutionEncapsulated — no reconstitution required.
Shelf life24 months from manufacture date
Dose per capsule500mcg
Capsule materialHPMC (Vegan)
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. doi:10.1007/s40279-026-02437-0. PubMed 02 Di H, Huang J, Zhang D, Ni F, Zheng R, Geng H Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026;195:171467. PMID: 41570941. doi:10.1016/j.peptides.2026.171467. PubMed 03 Faa G, Messana I, Coni P, Piras M, Pichiri G, Piludu M et al. Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review. Cells. 2024;13(13). PMID: 38994967. doi:10.3390/cells13131115. PubMed 04 Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, Gallyas F Jr et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. International immunopharmacology. 2023;116:109741. PMID: 36709593. doi:10.1016/j.intimp.2023.109741. PubMed 05 Naeem A, Knoer G, Avantaggiati ML, Rodriguez O, Albanese C Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β4 in medulloblastoma. International immunopharmacology. 2023;116:109785. PMID: 36720193. doi:10.1016/j.intimp.2023.109785. PubMed 06 Singh SK, Dwivedi SD, Yadav K, Shah K, Chauhan NS, Pradhan M et al. Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing. Biomedicines. 2023;11(2). PMID: 36831151. doi:10.3390/biomedicines11020613. PubMed 07 Chen X, Zhang C, Peng F, Wu L, Zhuo D, Wang L et al. Identification of glutamine as a potential therapeutic target in dry eye disease. Signal transduction and targeted therapy. 2025;10(1):27. PMID: 39837870. doi:10.1038/s41392-024-02119-1. PubMed 08 Zeng PM, Sun XY, Li Y, Wu WD, Huang J, Cao DD et al. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem cell reports. 2025;20(9):102601. PMID: 40816274. doi:10.1016/j.stemcr.2025.102601. PubMed 09 Maar K, Thatcher JE, Karpov E, Rendeki S, Gallyas F Jr, Bock-Marquette I Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. International journal of molecular sciences. 2025;26(9). PMID: 40362372. doi:10.3390/ijms26094131. PubMed 10 Nguyen J, Verma S, Vuong VT, Queener H, Coulson-Thomas VJ, Gesteira TF Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Investigative ophthalmology & visual science. 2025;66(14):31. PMID: 41235866. doi:10.1167/iovs.66.14.31. PubMed 11 Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular research. 2025;121(17):2747-2758. PMID: 41229390. doi:10.1093/cvr/cvaf223. PubMed 12 Li S, Fan T, Hao Z, Zhang Z, Han X, Li J et al. The Prognostic Significance of TMSB4X in Glioma Patients. International journal of general medicine. 2025;18:2923-2940. PMID: 40502330. doi:10.2147/IJGM.S521390. PubMed 13 Jin Z, Li H, Li J, Chang Y, Piao Z, Jin Q et al. Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution. Cellular signalling. 2025;136:112111. PMID: 40912522. doi:10.1016/j.cellsig.2025.112111. PubMed 14 Zhang X, Lin Y, Li H, Wang Q, Mu D Enhancing fat graft survival: thymosin beta-4 facilitates mitochondrial transfer from ADSCs via tunneling nanotubes by upregulating the Rac/F-actin pathway. Free radical biology & medicine. 2025;228:281-298. PMID: 39761767. doi:10.1016/j.freeradbiomed.2024.12.061. PubMed 15 Delcourt V, Garcia P, Chabot B, Aber N, Pescher M, Cacault M et al. Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection. Drug testing and analysis. 2025;17(7):1071-1077. PMID: 39314109. doi:10.1002/dta.3806. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

TB-500 is the synthetic version of the active region of Thymosin β-4, a 43-amino-acid actin-sequestering peptide studied for its role in cell migration, angiogenesis and tissue-repair signalling. Its biology has been examined across cardiac, corneal and regenerative models (Maar et al., 2025). Condor Research supplies it strictly as a Research Use Only reference compound for in vitro and animal studies, not for human or veterinary use.

TB-500 is a 43-residue thymosin β-4 fragment studied primarily as an actin-binding peptide governing cell motility and angiogenesis, whereas BPC-157 is a 15-residue gastric pentadecapeptide studied around cytoprotection and the nitric-oxide system. They sit in different mechanistic classes and address different research questions about tissue dynamics. Both are supplied strictly as research-use-only reference compounds, not for human or veterinary use.

No. Thymosin β-4 is the full 43-residue protein and one of the most abundant actin-binding molecules in many cells, with expression mapped across human organ development (Faa et al., 2024). TB-500 reproduces the active actin-binding region of that protein, making it a focused tool for studying the same pathways. Both are handled only as research-use-only reference materials, never for human or veterinary use.

TB-500 is studied around actin regulation, cell migration and angiogenesis, while KPV is a melanocortin-derived tripeptide studied chiefly for anti-inflammatory signalling in intestinal and dermal models. They illuminate different stages of the tissue-response question — structural remodelling versus inflammatory tone. Each is offered solely as a Research Use Only reference compound, not for human or veterinary use.

Yes. Condor Research supplies TB-500 strictly as a Research Use Only reference compound to professionals and institutions, not as a medicine, supplement or product for human or veterinary use. Buyers are responsible for confirming import legality in their own country. Questions: info@condorresearch.com.

The capsule is simply a pre-weighed solid format: 500mcg of TB-500 sealed in an HPMC (vegan) shell so each unit holds a precise, handling-ready quantity. This removes weighing steps at the bench and requires no reconstitution. The format is a laboratory convenience only and does not imply or permit human or veterinary consumption — for research use only.

No. The peptide is already encapsulated as a pre-measured solid, so no reconstitution is required for handling. Researchers prepare working solutions according to their own validated experimental protocols. The capsule is a laboratory format only and is not intended for human or veterinary use.

Each bottle contains 60 HPMC (vegan) capsules, with 500mcg of TB-500 per capsule at ≥99% (HPLC) purity. Every batch is independently third-party tested and a Certificate of Analysis is available on request. This specification describes a research reference material, not a product for human or veterinary use.

TB-500 has CAS No. 77591-33-4, molecular formula C212H350N56O78S and a molecular weight of 4963.44 g/mol. It is a 43-amino-acid acetylated peptide supplied as a white lyophilized powder, soluble in water. These values are provided for laboratory characterisation and research use only.

Yes. Every TB-500 batch is tested by an independent third-party laboratory by HPLC for identity and purity (≥99%), and each lot ships with a lot-specific Certificate of Analysis. To request the COA for your batch, contact info@condorresearch.com. This documentation supports research use only, not human or veterinary application.

Store at -20°C, protected from light and moisture, to preserve peptide integrity over the stated 24-month shelf life from the manufacture date. Stock is EU warehoused for reliable regional supply. For laboratory research use only. Not for human or veterinary use.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.8
43 verified reviews
5
79%
4
16%
3
5%
2
2%
1
0%
Apr 2026
Exactly what research needs

No marketing fluff — just characterised material with paperwork. The data sheet and CAS matched our records precisely.

J. Meijer · Biotech R&D · NL Verified purchase
Mar 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Mar 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Feb 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Jan 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase

Related compounds